Low-profile thoracic aortic endograft minimizes complications, increases patient pool Preliminary results of a clinical trial, presented today at the AATS 101st Annual Meeting, showed that a new, low-profile thoracic aortic endograft is safe and effective in the treatment of descending thoracic aortic aneurysm or penetrating atherosclerotic ulcer (PAU) diseases. A multi-disciplinary team, led by both cardiac and vascular surgeons as co-investigators, conducted the study in 36 centers in the United States and Japan, enrolling patients between 2016 and 2019. The trial aimed to measure safety and efficacy of the RELAY®Pro endovascular device, a second-generation product featuring a dramatically reduced profile and a non-bare stent (NBS) configuration.